Health Technology

Norrsken VC

Check: Norrsken VC's live site publishes €1M–€10M early-stage and growth tickets. This is the firm's current range, not Agate's personal check promise; exact initial versus follow-on sizing, ownership and vehicle should be confirmed for each opportunity.

Agate backs rapidly scalable businesses where solving a major social or environmental problem improves commercial performance. Her finance, fintech-startup and education experience combines with Norrsken's measurable-impact discipline: the problem must be material, the technology must outperform legacy economics, the business must support venture returns and impact must scale in proportion to company growth.

Norrsken VC

Check: Norrsken VC currently states €1M–€10M early-stage and growth tickets. This is the firm's range, not Tove's personal promise. Confirm initial ticket, follow-on reserves, ownership and stage with the team.

Tove backs ambitious European technology companies whose commercial growth directly improves outcomes for people or planet. Her Bain private-equity background and early impact roles add rigorous market and diligence discipline. Current health-AI work highlights companies that combine deep sector expertise, proprietary data and measurable time or cost improvements in critical systems such as clinical trials.

Maki.vc (Web3)

Check: Maki Fund III currently states €300K–€3M initial tickets in pre-seed and seed rounds below €5M, with follow-on reserves. This is the active firm's range, not Ilkka's personal or current new-deal authority; his stated remit focuses on existing portfolio companies.

Ilkka co-built Maki around entrepreneurial DNA, technical depth, non-consensus first-round decisions and Nordic founders with global category ambition. His documented portfolio work spans gaming, smartphone diagnostics, industrial ultrasound, simulation and glasses-free mixed reality—teams translating difficult science or engineering into a product with striking customer value. His current role is portfolio advisor rather than the lead for new investments.

Lux Capital

Check: Not applicable to Nat's events role. Lux invests across stages, but no personal allocation authority or check size belongs to this profile. Founder financing pitches should go to Lux's investment team.

Nat designs the convening layer around Lux's frontier-science and technology network. Her work brings together founders, researchers, executives, investors, journalists and creative leaders in focused formats such as AI, AI-biology and health-intelligence summits. The operating thesis is that carefully curated, content-rich gatherings create trust, knowledge exchange and useful founder connections. It is a platform thesis, not a personal investment thesis.

Norrsken VC

Check: Norrsken VC currently publishes €1M–€10M early-stage and growth tickets. This is a firm range rather than Anna's personal authority. Confirm geography, initial ticket, ownership, reserves and impact qualification through the firm's pitch process.

Anna combines Norrsken's impact-return mandate with eight years of strategy, operations and international market expansion at Spotify. Her likely value is testing whether an early impact company can turn a strong product into repeatable multi-market growth without losing operational discipline or the causal link between usage and measurable impact.

Indico Capital

Check: Indico's live technology mandate states mostly Pre-Seed through Series A investments of €500K–€10M, with selective Series B/C participation. This is the firm's range rather than João's personal authority; founders should confirm vehicle, initial ticket and reserves.

João evaluates Southern European technology companies through a combined engineering, investment-banking, private-equity and venture lens. The documented firm mandate favors globally ambitious founders in Portugal, Spain and Italy, mostly from Pre-Seed to Series A, whose technical differentiation can become a durable international business rather than a local feature company.

Indico Capital

Check: Indico currently publishes €500K–€10M technology investments, mostly from Pre-Seed through Series A with selective Series B/C. This is the live firm range, not Rui's personal check authority; exact sizing and vehicle should be confirmed directly.

Rui brings long-running Portuguese institutional venture experience to Indico's early-stage Southern European technology mandate. Public evidence supports a broad rather than narrow personal sector remit: find exceptional founders in Portugal, Spain and Italy, help them build for global markets from inception and reserve later-stage capital for the strongest validated opportunities.

Indico Capital

Check: Indico's current technology range is €500K–€10M, mostly Pre-Seed through Series A and selectively Series B/C. This is firm-level guidance, not Rui's personal commitment range; founders should confirm the applicable fund, initial size and reserves.

Rui combines venture investing with transaction and corporate-finance discipline. Within Indico's mandate, that supports globally ambitious Southern European technology companies from early validation through selective growth: the product and founders must be exceptional, but market scale, financing logic, governance and the economics of building an enduring international company must also hold together.